APA (7th ed.) Citation

MS, B., BG, R., SI, S., B, J., CC, L., F, V., . . . J, C. (2022). Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer, 128(24), 4203. https://doi.org/10.1002/cncr.34493

Chicago Style (17th ed.) Citation

MS, Brose, et al. "Cabozantinib for Previously Treated Radioiodine-refractory Differentiated Thyroid Cancer: Updated Results from the Phase 3 COSMIC-311 Trial." Cancer 128, no. 24 (2022): 4203. https://doi.org/10.1002/cncr.34493.

MLA (9th ed.) Citation

MS, Brose, et al. "Cabozantinib for Previously Treated Radioiodine-refractory Differentiated Thyroid Cancer: Updated Results from the Phase 3 COSMIC-311 Trial." Cancer, vol. 128, no. 24, 2022, p. 4203, https://doi.org/10.1002/cncr.34493.